Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr 6;10(7):e016947.
doi: 10.1161/JAHA.120.016947. Epub 2021 Mar 17.

Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study

Arnaud D Kaze  1 , Prasanna Santhanam  2 , Solomon K Musani  3 , Rexford Ahima  2 , Justin B Echouffo-Tcheugui  2   4
Affiliations
Randomized Controlled Trial

Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study

Arnaud D Kaze et al. J Am Heart Assoc. .

Erratum in

Abstract

Background Metabolic dyslipidemia (high triglyceride) and low high-density lipoprotein cholesterol (HDL-C) is highly prevalent in type 2 diabetes mellitus (T2DM). The extent to which diabetes mellitus-related abnormalities in the triglyceride-HDL-C profile associates with cardiovascular disease (CVD) risk is incompletely understood. We evaluated the associations of triglyceride and HDL-C status with CVD outcomes in individuals with T2DM. Methods and Results We analyzed data from 4199 overweight/obese adults with T2DM free of CVD with available data on triglyceride and HDL-C at baseline (2001-2004) in the Look AHEAD (Action for Health in Diabetes) study. We used Cox proportional models to estimate hazard ratios (HRs) and 95% CIs of: (1) composite CVD outcome (myocardial infarction, stroke, hospitalization for angina, and/or death from cardiovascular causes); (2) coronary artery disease events; and (3) cerebrovascular accidents (stroke). Of the 4199 participants, 62% (n=2600) were women, with a mean age of 58 years (SD, 7), and 40% (n=1659) had metabolic dyslipidemia at baseline. Over a median follow-up of 9.5 years (interquartile range, 8.7-10.3), 500 participants experienced the composite CVD outcome, 396 experienced coronary artery disease events, and 100 experienced stroke. Low HDL-C was associated with higher hazards of the composite CVD outcome (HR, 1.36; 95% CI, 1.12-1.64 [P=0.002]) and coronary artery disease events (HR, 1.46; 95% CI, 1.18-1.81 [P=0.001]) but not stroke (HR, 1.38; 95% CI, 0.90-2.11 [P=0.140]). Compared with patients with normal triglyceride and normal HDL, participants with metabolic dyslipidemia had higher risks of the composite CVD outcome (HR, 1.30; 95% CI, 1.03-1.63 [P=0.025]) and coronary artery disease events (HR, 1.48; 95% CI, 1.14-1.93 [P=0.003]) but not stroke (HR, 1.23; 95% CI, 0.74-2.05 [P=0.420]). Conclusions In a large sample of overweight/obese individuals with T2DM, metabolic dyslipidemia was associated with higher risks of CVD outcomes. Our findings highlight the necessity to account for metabolic dyslipidemia in CVD risk stratification among patients with T2DM. Registration URL: https://www.lookaheadtrial.org; Unique identifier: NCT00017953.

Keywords: cardiovascular disease; diabetes mellitus; metabolic dyslipidemia; type 2.

PubMed Disclaimer

Conflict of interest statement

The Look AHEAD study was conducted by the Look AHEAD Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the Look AHEAD reported here were supplied by the NIDDK Central Repositories. This manuscript was not prepared in collaboration with Investigators of the Look AHEAD study and does not necessarily reflect the opinions or views of the Look Ahead Study, the NIDDK Central Repositories, or the NIDDK.

Look AHEAD was conducted by the Look AHEAD Research Group and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); the National Heart, Lung, and Blood Institute (NHLBI); the National Institute of Nursing Research (NINR); the National Institute of Minority Health and Health Disparities (NIMHD); the Office of Research on Women's Health (ORWH); and the Centers for Disease Control and Prevention (CDC). The data (and samples) from Look AHEAD were supplied by the NIDDK Central Repositories. This manuscript was not prepared under the auspices of the Look AHEAD and does not represent analyses or conclusions of the Look AHEAD Research Group, the NIDDK Central Repositories, or the NIH

Figures

Figure 1
Figure 1. Cumulative proportion of participants with cardiovascular disease (CVD) events by triglyceride and high‐density lipoprotein (HDL) cholesterol status in the Look AHEAD (Action for Health in Diabetes) study.
CVD event is a composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, and death from cardiovascular causes.
Figure 2
Figure 2. Hazard ratios (HRs) of cardiovascular outcomes by triglyceride–high‐density lipoprotein (HDL) cholesterol status and low‐density lipoprotein (LDL) cholesterol categories in the Look AHEAD (Action for Health in Diabetes) study.
Composite cardiovascular disease (CVD) outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for angina. Coronary artery disease (CAD) outcome was the first occurrence of a composite of MI and coronary artery bypass grafting. Stroke outcome was the first occurrence of a composite of ischemic and/or hemorrhagic stroke. NA indicates not available. HRs were obtained from Cox proportional hazard models with adjustment for age, sex, race/ethnicity, randomization arm, body mass index, current smoking (yes/no), alcohol drinking (ounces per week), systolic blood pressure, use of antihypertensive medications (yes/no), glycated hemoglobin, and duration of diabetes mellitus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics‐2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528. DOI: 10.1161/CIR.0000000000000659. - DOI - PubMed
    1. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–1029. DOI: 10.1001/jama.2015.10029. - DOI - PubMed
    1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504. DOI: 10.1056/NEJMoa040583. - DOI - PubMed
    1. Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620. DOI: 10.2337/diacare.20.4.614. - DOI - PubMed
    1. Association AD. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27:s68–s71. DOI: 10.2337/diacare.27.2007.S68. - DOI - PubMed

Publication types

MeSH terms

Associated data

-